This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment

Herbert Y. Meltzer, MD; Michael Davidson, MD; Alexander H. Glassman, MD; and W. Victor R. Vieweg, MD

Published: September 1, 2002

Article Abstract

The atypical antipsychotic drugs are a major advance in the treatment of psychosis in spite of concernsabout metabolic and cardiovascular side effects that affect morbidity and mortality. Concernsabout weight gain, hypoglycemia, diabetes, and increases in lipids as well as sudden death due totorsades de pointes and other cardiovascular events can temper enthusiasm about the atypical antipsychotics.The challenge for the clinician is to weigh the benefits and risks for each drug for each patientand develop a treatment plan with the individual patient in mind. This article discusses both risks andbenefits of antipsychotic treatment and presents a treatment algorithm to aid the clinician in choosingmedications for the psychotic patient.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...